New York Blood Center, Inc.

Other

California Institute of Technology

Health Research, Inc.

Nathan Strick

Alexander Robert Neurath

Shibo Jiang

Asim Kumar Debnath

Gordon Jay Dow

Yasmin M Thanavala

Stephen B Kent

A Robert Neurath

Michael W Pride

Paul Haberfield

Yun-Yao Li

A novel treatment for topical inflammatory conditions such as acne, eczema, shingles, insect bites and hives is provided, consisting of the application of a pharmaceutical cream or ointment which incorporates hydroxypropyl methylcellulose acetate succinate ('HPMCAS') in a micronized form and which preferably contains one or more thickeners, a bio-adhesive agent and water so that the formulation, when applied, can stick to the area to be treated.

Composition for the treatment of inflammatory conditions

An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one pectin, such as an apple pectin, and optionally at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.

Biodegradable microbicidal vaginal barrier device

An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.

A method for immunizing a human against hepatitis B virus comprising administering to the human a vaccine comprising a hepatitis B virus surface antigen, wherein included in the vaccine is one or more antigens of non-permitted variant sequences within residues S(139-147) of the hepatitis B virus surface antigen.

Method of immunizing against hepatitis B virus

A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

'Methods and compositions for decreasing the frequency of HIV,

A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

Method for decreasing the frequency of transmission of viral infections

A method for the screening of a test compound for inhibiting the binding of a CD4-HIV 1 complex to HIV-1 second receptors, comprising: (a) preparing a magnetic ligand by mixing a magnetic, CD4-containing substrate with HIV-1, (b) mixing the magnetic ligand from step (a) with a test compound, (c) adding cells that express the HIV-1 second receptors to the mixture from step (b), (d) separating cells with bound magnetic ligands from cells without bound magnetic ligands by contact with a magnetic separator, and (e) quantifying the cells with bound magnetic ligands and quantifying the cells without bound magnetic ligands.

Methods for screening of test compounds for inhibiting binding of a

A method for the rapid screening of a drug targeted to the V3 hypervariable loop of the human immunodeficiency virus type 1 or type 2 envelope glycoprotein gp 120 comprising measuring the inhibitory effect of the drug on the interaction between gp 120 (or an antigen comprising the V3 hypervariable loop of HIV 1 gp 120 or HIV 2 gp 120) and antibodies specific for the V3 hypervariable loop, and anti-HIV chemotherapy with drugs binding to the V3 hypervariable loop.

Method for the prescreening of drugs targeted to the V3 hypervariable

A process for the detection of antibodies to HTLV III/LAV comprising:

Immunoassays for antibodies which bind to the acquired immunodeficiency

A reagent for an ELISA determination of an antibody, the reagent comprising a peptide covalently linked to beta-lactamase. The reagent can be used in the following method to detect antibodies in a sample which involves

Peptide-beta-lactamase conjugates for enzyme-linked immunoassays

A process for detecting the presence of an antigen in a specimen is described, which process comprises:

Growing community of inventors

Oceanside, NY, United States of America

Nathan Strick